TABLE 2.

RESTING OR BASELINE NASAL PD

Day of Dosing	Premature Stop Group: Gentamicin	Premature Stop Group: Tobramycin	Control Group: Gentamicin and Tobramycin
D01 “pre” values	−36.18 (17.16)	−37.73 (10.87)	−42.09 (10.12)
Day 07 (D07–D01)	2.43 (16.89)	3.48 (6.35)	6.40 (14.17)
Day 14 (D14–D01)	2.27 (16.09)	0.12 (9.44)	2.19 (18.21)
Post-values (D28–D01)	−4.30 (16.51)	1.45 (9.10)	3.88 (14.12)

Definition of abbreviation: PD, potential difference.

Change in PD from pretreatment in premature stop subjects during gentamicin and tobramycin treatment, and in control subjects during treatment (with either aminoglycoside). Values in the “Day 01 pretreatment” row are the actual mean resting PD (± SD). Values below are changes from the Day 01 value (average values of both nostrils per subject). Day 07 and Day 14 are “on treatment.” Positive changes in PD reflect improvements in CFTR function.